Renal Cell Carcinoma

Local therapy for mRCC

Earn accreditation points

Finish 5 case(s) answer 10 question(s) and Earn 1 credit.

Continue
Objectif pédagogique: Identify patients with metastatic ccRCC who will benefit the most from immediate, deferred or no cytoreductive nephrectomy (CN) and metastasis-directed therapy.
Spécialité: Urology, Medical oncology, Clinical oncology
Public cible: Specialists (CME: basic, intermediate), Residents (senior)
Dernière mise à jour: May 2024
Contexte:

The role of CN and metastasis-directed therapy (including surgery, ablative therapies and radiotherapy) in the treatment of mRCC is evolving. However, the precise role of CN and its timing in relation to systemic therapy remains controversial.